Galecto to Participate in Upcoming Investor Conferences
Galecto Inc (NASDAQ: GLTO), a clinical-stage biotechnology company developing treatments for cancer and severe liver diseases, has announced its participation in three major upcoming investor conferences.
The company will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, from 8:40-9:10 AM in a virtual format, featuring both a corporate presentation and one-on-one meetings. A live webcast will be available on Galecto's investor relations website, with replay access for 90 days.
Additionally, Galecto will attend the Leerink Partners Global Healthcare Conference on March 12 in Miami Beach, Florida, conducting one-on-one meetings, and the 37th Annual ROTH Conference on March 17-18 in Dana Point, CA, where they will deliver a corporate presentation and hold one-on-one meetings.
Galecto Inc (NASDAQ: GLTO), un'azienda biotecnologica in fase clinica che sviluppa trattamenti per il cancro e gravi malattie epatiche, ha annunciato la sua partecipazione a tre importanti conferenze per investitori in arrivo.
L'azienda presenterà alla 35ª Conferenza Annuale Oppenheimer sulla Salute e le Scienze della Vita il 12 febbraio 2025, dalle 8:40 alle 9:10 AM in formato virtuale, comprendente sia una presentazione aziendale che incontri one-to-one. Una webcast in diretta sarà disponibile sul sito web delle relazioni con gli investitori di Galecto, con accesso alla registrazione per 90 giorni.
In aggiunta, Galecto parteciperà alla Conferenza Globale sulla Salute dei Leerink Partners il 12 marzo a Miami Beach, Florida, conducendo incontri one-to-one, e alla 37ª Conferenza Annuale ROTH il 17-18 marzo a Dana Point, CA, dove terranno una presentazione aziendale e incontri one-to-one.
Galecto Inc (NASDAQ: GLTO), una empresa de biotecnología en etapa clínica que desarrolla tratamientos para el cáncer y enfermedades hepáticas severas, ha anunciado su participación en tres importantes conferencias para inversores próximamente.
La compañía se presentará en la 35ª Conferencia Anual Oppenheimer de Ciencias de la Salud el 12 de febrero de 2025, de 8:40 a 9:10 AM en formato virtual, que incluirá tanto una presentación corporativa como reuniones uno a uno. Se dispondrá de una transmisión en vivo en el sitio web de relaciones con inversores de Galecto, con acceso a la repetición durante 90 días.
Además, Galecto asistirá a la Conferencia Global de Salud de Leerink Partners el 12 de marzo en Miami Beach, Florida, llevando a cabo reuniones uno a uno, y a la 37ª Conferencia Anual ROTH el 17 y 18 de marzo en Dana Point, CA, donde realizarán una presentación corporativa y reuniones uno a uno.
Galecto Inc (NASDAQ: GLTO)는 암 및 심각한 간 질환 치료제를 개발하는 임상 단계의 생명공학 회사로, 다가오는 세 가지 주요 투자자 회의에 참여할 것이라고 발표했습니다.
회사는 Oppenheimer 제35회 연례 헬스케어 생명과학 회의에서 2025년 2월 12일 오전 8:40부터 9:10까지 가상 형식으로 발표하며, 기업 프레젠테이션과 일대일 미팅이 포함됩니다. Galecto의 투자자 관계 웹사이트에서 실시간 웹캐스트를 이용할 수 있으며, 90일 동안 다시 볼 수 있는 기능이 제공됩니다.
덧붙여서, Galecto는 플로리다 마이애미 비치에서 3월 12일 Leerink Partners 글로벌 헬스케어 회의에 참석하여 일대일 미팅을 진행하며, 캘리포니아 다나 포인트에서 3월 17일부터 18일까지 열리는 제37회 ROTH 회의에서도 기업 프레젠테이션과 일대일 미팅을 가질 예정입니다.
Galecto Inc (NASDAQ: GLTO), une entreprise de biotechnologie en phase clinique développant des traitements pour le cancer et des maladies hépatiques sévères, a annoncé sa participation à trois grandes conférences pour investisseurs à venir.
L'entreprise présentera à la 35ème Conférence Annuelle Oppenheimer sur la Santé et les Sciences de la Vie le 12 février 2025, de 8h40 à 9h10 en format virtuel, comprenant une présentation d'entreprise et des réunions individuelles. Un webinaire en direct sera disponible sur le site des relations avec les investisseurs de Galecto, avec un accès à la rediffusion pendant 90 jours.
De plus, Galecto assistera à la Conférence Globale sur la Santé de Leerink Partners le 12 mars à Miami Beach, Floride, en menant des réunions individuelles, et à la 37ème Conférence Annuelle ROTH les 17 et 18 mars à Dana Point, CA, où ils tiendront une présentation d'entreprise et des réunions individuelles.
Galecto Inc (NASDAQ: GLTO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das Behandlungen für Krebs und schwere Lebererkrankungen entwickelt, hat seine Teilnahme an drei wichtigen bevorstehenden Investorenkonferenzen angekündigt.
Das Unternehmen wird am 35. Annual Oppenheimer Healthcare Life Sciences Conference am 12. Februar 2025 von 8:40 bis 9:10 Uhr in einem virtuellen Format teilnehmen, das sowohl eine Unternehmenspräsentation als auch One-on-One-Meetings umfasst. Ein Live-Stream wird auf der Investor Relations-Website von Galecto verfügbar sein, mit 90 Tagen Replay-Zugriff.
Darüber hinaus wird Galecto an der Leerink Partners Global Healthcare Conference am 12. März in Miami Beach, Florida, teilnehmen und One-on-One-Meetings durchführen, sowie an der 37. Annual ROTH Conference am 17.-18. März in Dana Point, CA, wo sie eine Unternehmenspräsentation halten und One-on-One-Meetings veranstalten werden.
- None.
- None.
BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences:
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Format: Corporate Presentation and One-on-One Meetings
Date and Time: Wednesday, February 12 at 8:40-9:10 AM
Location: Virtual
A live webcast of the presentation will be available via the Upcoming Events section of the Company’s investor relations website at https://ir.galecto.com/news-and-events/events. An archived replay will be accessible for 90 days following the event.
Leerink Partners Global Healthcare Conference
Format: One-on-One meetings
Date and Time: Wednesday, March 12
Location: Miami Beach, Florida
37th Annual ROTH Conference
Format: Corporate Presentation and One-on-One Meetings
Date and Time: Monday, March 17, and Tuesday, March 18
Location: Dana Point, CA
About Galecto
Galecto is a clinical-stage biopharmaceutical company committed to realizing the promise of novel treatments for cancer and liver diseases. The Company’s pipeline consists of first-in-class small molecule drug candidates that target cancer and fibrosis signaling pathways, including (i) an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; (ii) an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and (iii) as recently announced, a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of AML, which Galecto acquired from Bridge Medicines. Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.
For more information, contact:
Investors Contact:
Sandya von der Weid
svonderweid@lifesciadvisors.com
+41 78 680 0538
FAQ
When and where is Galecto (GLTO) presenting at the Oppenheimer Healthcare Conference 2025?
How long will the GLTO Oppenheimer Conference webcast replay be available?
Which investor conferences is Galecto (GLTO) attending in March 2025?
Where can investors access Galecto's (GLTO) Oppenheimer Conference presentation webcast?
